A growing body of research indicates that the menopausal transition is a period of increased vulnerability to depressive illness. Â Some women have experienced episodes of major depressive disorder (MDD) earlier in life and experience recurrent [...]
Which treatment is best for managing menopausal sleep problems? We tend to think of estrogen replacement therapy as being the best option for all menopausal symptoms; however, there are other options for managing menopausal symptoms, [...]
Several recent articles indicate that the burden of menopausal symptoms is greater than generally perceived.  About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the [...]
A recent paper from the European Menopause and Andropause Society (EMAS) reviews non-hormonal therapy options for the treatment of  menopausal vasomotor symptoms. This EMAS position paper provides guidance for treaters managing peri- and postmenopausal women [...]
Over the last decade, various studies have evaluated the effectiveness of acupuncture for the treatment of menopausal vasomotor symptoms. In a recent meta-analysis, studies that reported on the frequency or severity of hot flashes, menopause-related symptoms assessed using the Menopause Rating Scale (MRS), and quality of life (QoL) assessed using the Menopause-Specific Quality of Life (MSQoL) questionnaire were included. Twelve studies with a total of 869 participants met the inclusion criteria and were included in the final analysis.
Studies evaluating the relationship of caffeine to vasomotor symptoms have yielded conflicting results.
While there are concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain settings. A study presented this week at the Endocrine Society’s annual meeting which analyzed data from 43 randomized clinical trials suggests that menopausal hormone-replacement therapy does not appear to affect mortality either positively or negatively.
Up to 80% of women experience vasomotor symptoms (VMS) as they transition into the menopause phase. While clinical guidelines suggest that VMS typically last from 6 months to 2 years, we often see women with VMS lasting for a much longer period of time. To more accurately assess the duration of VMS in perimenopausal women, researchers analyzed data from 1449 women included in the Study of Women's Health Across the Nation (SWAN), an observational study of women entering menopause. Here is a summary of the key findings:
A recent study has explored the association between vitamin D levels and vasomotor symptoms in a group of postmenopausal women.
Last year, the FDA approved the first non-hormonal treatment for hot flashes – a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine which was marketed under the name of Brisdelle. A new study [...]
